Zapping pancreatic tumors with heat: a Needle-Sized hope
NCT ID NCT07585032
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a procedure called EUS-guided radiofrequency ablation (EUS-RFA) for people with pancreatic insulinoma, a rare tumor that causes low blood sugar. The procedure uses a thin needle passed through an endoscope to deliver heat and destroy the tumor. Researchers want to see if it is safe and effective at relieving symptoms, with the goal of offering a less invasive alternative to surgery. The trial is currently recruiting 20 participants in Sweden.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EUS-guided radiofrequency ablation (EUS-RFA)
- What this could lead to
- If it works, this could offer a less invasive treatment option for pancreatic insulinoma, potentially reducing symptoms and avoiding major surgery.
- What could go wrong
- This is a small, early-phase trial with only 20 participants. The procedure may not fully destroy the tumor, and there are risks like bleeding, infection, or pancreatitis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients referred to Sahlgrenska UH for the diagnosis and treatment of pancreatic insulinoma.
- Ages
-
15 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Insulinoma verified by pathology (often from EUS-FNB-sampling) Exclusion Criteria: * Patients unwilling to participate * Patients unable to understand and obtain written informed conscent * Severe comorbidity
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Insulinoma; pancreas are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sahlgrenska Univeristy Hospital
RECRUITINGGothenburg, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.